EDELSTAM GRETA
No ORCID on file
· 57 papers in corpus
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…
2011
A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50 % or more while not affecting a corresponding TNF-a related activity level by more than 30 %…